Evidence map›Paper›PMID 40597169›Full record

ArticleWorld journal of surgical oncology2025

A clinical investigation of extracranial metastases in 17 cases of intracranial solitary fibrous tumors.

Chao Wang, Jiang Li, Gang Li, Da-Yun Feng, Ying-Xi Wu, Jun-Ting Li, Di Yang, Jia-Hua Zhou

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao Wang *Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.
Jiang Li *Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.
Gang Li *Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.
Da-Yun FengDepartment of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.
Ying-Xi WuDepartment of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China.
Jun-Ting LiDepartment of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Di YangDepartment of Radiology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China. yangdimed@163.com.
Jia-Hua ZhouDepartment of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China. zhoujhtd@163.com.

Funding

Tangdu Youth Independent Innovation Science Fund 2023CTDQN005
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the clinical features, pathological progression, and treatment strategies for distant metastases of intracranial solitary fibrous tumors (ISFTs).

methodsA retrospective analysis was conducted on 17 patients with ISFTs and documented distant metastases, treated at a single institution between 2001 and 2023. Disease progression and treatment outcomes were systematically reviewed.

resultsOf the 17 patients, 14 experienced in situ recurrence following resection of the primary intracranial tumor, necessitating a total of 41 intracranial lesion resections. Based on initial pathological assessments, the cases were classified as grade 1 (n = 4), grade 2 (n = 10), and grade 3 (n = 3) ISFTs. Over time, all but one grade 1 and grade 2 tumor were reclassified as grade 3. Following initial resections, 13 patients underwent local radiotherapy and 2 received systemic chemotherapy prior to the development of distant metastases. After metastasis, 8 patients underwent metastatic tumor resection, while 7 received conservative treatment, and 2 did not undergo any intervention. A total of 10 patients, including 2 who withdraw treatment, were followed until the end point. The average survival time for this group was 106 months (range: 23-190 months), with an average survival of 20.89 months (range: 2-60 months) following the diagnosis of distant metastases. Mortality was attributed to functional failure of vital organs, tumor burden, systemic failure, or cachexia. The remaining 7 cases underwent active treatment and are still being monitored. The average total follow-up duration was 145.57 months (range: 95-256 months), while the average follow-up time after distant metastasis diagnosis was 33.42 months (range: 13-72 months).

conclusionSurgical resection remains the primary treatment modality for ISFTs, with adjuvant radiotherapy recommended to delay recurrence. Recurrent tumors frequently exhibit pathological grade progression. Gamma knife radiosurgery is effective for small recurrences, while larger tumors often require repeated surgical resections to manage the primary lesion. The development of distant metastases signifies advanced disease, requiring a multidisciplinary approach that incorporates surgical resection, radiotherapy, and targeted therapies. Distant metastasis remains the primary cause of mortality following active treatment.

Indexed as

Brain NeoplasmsNeoplasm Recurrence, LocalSolitary Fibrous TumorsAdultAgedCombined Modality TherapyDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung AdultChemotherapyHemangiopericytoma (HPC)Intracranial solitary fibrous tumor (ISFT)MetastasisRadiotherapySurgeryTargeted drugTargeted therapy

Identifiers

PMID40597169
PMCPMC12220498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.